Press release 16 November 2021. Backahill enters into an agreement to sell AB Cernelle. Backahill AB has entered into an agreement to sell all shares in the subsidiary AB Cernelle to the German pharmaceutical group Dermapharm AG. “We have had a long and very interesting time as owners of Cernelle, which has developed very positively under the management of CEO Ken Tinebo. In Dermapharm, Cernelle gets an owner who can continue to develop and support the company´s expansion, both geographically and product wise that it has strategically worked towards for a number of years now. The sale of Cernelle [Read more]

Cernelle enters China. AB Cernelle, in partnership with MeiRui, a leading Chinese pharmaceutical company specialising in urology, has received approval for Shenitong®, which is an herbal medicinal product for the treatment of benign prostate diseases. Both companies are now preparing for the market launch of Shenitong®, with the product expected to be available on the Chinese market beginning of 2022. There are 700 million men in China aged between 15 and 64 years. Around 40 per cent, or 280 million men, are expected to experience symptoms associated with benign prostate conditions. Shenitong® (=Cernitol®Novum) is the only medicinal product that [Read more]

Cernelle – a 100% fossil-free companyBiogas instead of natural gas, charging posts for cars, switching to LED lighting and detailed energy measurement. Following several years of concerted effort to reduce its environmental impact, pharmaceutical company Cernelle located outside of Ängelholm, Sweden, is now completely fossil free as regards its process and heating.AB Cernelle has recently signed an agreement with energy company Öresundskraft on delivery of biogas to replace natural gas in its production of herbal pharmaceutical products and to heat the facility’s premises.Other measures include the installation of charging posts for company cars and staff cars, a switch to LED [Read more]

COVID-19 and supply of medicines As the coronavirus outbreak continues to evolve globally, Cernelle is implementing the necessary precautions to safeguard the continued supply of our medicines and provide treatment for the people who need our help. Our supply chain remains intact, and we have not experienced any supply disruptions. The health and safety of employees at Cernelle is one of our top priorities, therefore we are following the recommendations from the government. Strict hygiene measures are taken to ensure safety at our sites. Delivering the required medicine to people living with prostate diseases while keeping our employees and [Read more]

Cernitol Novum is launched in France Cernitol Novum is now available in France under the brand name Cernitol 47 mg. Cernelle is expanding internationally by entering a large and promising market. The French have great confidence and long history of using herbal pharmaceuticals. Cernitol is the first drug approved using pollen extract, as a the active pharmaceutical ingredient, to effectively treat symptoms caused by benign prostate hyperplasia (BPH). It is estimated that 2 million men in France suffer from benign prostate diseases. Prevalence data shows that one out of two men between 55 and 70 years and eight out of [Read more]

New facilities to manage ongoing expansionEnd of 2018, Cernelle’s team moved from a traditional to a modern office space and a new laboratory, both about 1000 sqm. Cernelle’s modern and dynamic spaces are designed to increase growth capacity, work effectiveness and communication between co-workers.« We are growing rapidly and therefore needed a larger office space and a new laboratory to accommodate our growing team and an international expansion. » says Ken Tinebo, CEO.With conference rooms in different sizes, several rooms for individual work, various spaces for team work, Cernelle’s new workspace is designed to meet the team’s different tasks and [Read more]